SDGR · Schrodinger, Inc.
$19.85
+2.18 (+12.34%)
At close · Aug 19
Market Cap
$1.30B
Shares
74.81M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$19.85
Open$18.12
Day$18.12–19.92
52W close$11.07–22.52
Avg vol 30d1.1M
Short int11.0M · 14.7% float · 12.8d
Short vol58%
Last earningsAug 5, 2026
DataFeb 2020–Aug 2026
Filing10-Q · Aug 5
Up next
Next earnings call
Nov 5, 2026
Est · unconfirmed
· in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 5, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+32%
above
Price vs 50-day avg
+23%
above
RSI (14)
73
overbought
MACD trend
Positive
52-week position
77%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+32%
trailing
6-month return
+56%
trailing
YTD return
+11%
this year
Relative strength
+44%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $16 › 200d $15 — 50d above 200d
Institutional flow
Flat
0% holders QoQ · +44 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
14.72% of float · ▲ +4.0% MoM · 12.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
230 holders — mid 3-yr range
Squeeze score
84
high risk · 0–100
Fundamentals
Revenue growth
+23%
Y/Y
Gross margin
56%
contracting
EPS growth
+45%
Y/Y
Free cash flow
$12.5M
Balance sheet
$230.5M
net cash
Quant / Vol
risk profile
Volatility
54%
annualized · 1-yr
Max drawdown
−51%
past year
ATR
4.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 5, 2026
fiscal year ending December 31, 2026
ACV
Initiated
$218M – $228M
Drug discovery revenue
Initiated
$65M – $75M
third quarter of 2026
ACV, excluding contribution ACV
Initiated
$41M – $45M
Prior guidance
period ended
· from the 8-K filed May 5, 2026
ACV (annual contract value), exclusive of contribution ACV
· second quarter of 2026
$19M – $23M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+32%
Bullish
Price vs 50-day avg
+23%
Bullish
RSI (14)
73
Bearish
MACD trend
Positive
Bullish
52-week position
77%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 1 of 6
Trend (MA cross)
No cross
50d $16 › 200d $15 — 50d above 200d
Institutional flow
Flat
0% holders QoQ · +44 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
14.72% of float · ▲ +4.0% MoM · 12.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
230 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $11
Now $20 · 77%
Range high $23
vs 200-day avg +32%
vs 50-day avg +23%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| ACV | $29.6M | second quarter 2026 | — |
|
|
|||
| ACV excluding contribution ACV | $22.6M | second quarter 2026 | — |
| Hosted revenue as % of software revenue | 47% | second quarter 2026 | — |
| Software gross margin | 69% | Q1 2026 | — |
| ACV per Commercial Customer (>$1M ACV) | $3.9M | Full Year 2025 | — |
| Adjusted EBITDA non-GAAP | -$114.9M | Full Year 2025 | — |
| Commercial ACV | $177.4M | Full Year 2025 | — |
| Gross Dollar Retention (Commercial Customers) | 96% | Full Year 2025 | — |
| Net Dollar Retention (Commercial Customers) | 100% | Full Year 2025 | — |
| Number of collaborators since 2018 | 20 | Full Year 2025 | — |
| Number of Commercial Customers (>$1M ACV) | 27 | Full Year 2025 | — |
| Ongoing programs eligible for royalties | 16 | Full Year 2025 | — |
| Top 20 Pharma ACV | $80.8M | Full Year 2025 | — |
| Total annual contract value (ACV) | $198.5M | Full Year 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Health Information Services — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SDGR
this stock
Schrodinger, Inc.
|
$1.30B | +11.0% | +23.3% | — | 14.7% |
|
VEEV
Veeva Systems Inc
|
$39.43B | +12.4% | +28.1% | 43.0 | 4.5% |
|
PMDIY
Pro Medicus Ltd./ADR
|
$13.02B | -24.9% | — | — | 0.0% |
|
BTSG
BrightSpring Health Services, Inc.
|
$11.77B | +58.4% | +28.2% | 36.1 | 4.2% |
|
TEM
Tempus AI, Inc.
|
$8.91B | +3.7% | +83.4% | — | 18.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SDGR | +6.6% | +32.1% | +55.6% | +31.1% | +11.0% |
| SPY | -0.4% | +2.9% | +11.6% | +3.0% | +12.8% |
| vs SPY | +7.0% | +29.2% | +44.0% | +28.2% | -1.8% |
Key facts
CIK
1490978
CUSIP
80810D103
13F (30d)
230 filings
212 filers
Visit website
Investor relations